ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens
Hørsholm, Denmark, 3 July 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") a late preclinical stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for the patent "Glyco-Engineered Immunization Antigens”. Granting of the patent in the U.S. validates the patentability of ExpreS2ion’s technology platform patent portfolio, thus representing a significant value inflection point for the company.
Although the mechanism of action may differ, we have demonstrated that altering the surface properties of select vaccine candidates can enhance the immune response in animals to levels previously achieved only through nanoparticle presentation of the vaccine protein. We are continuing to investigate both the underlying mechanisms and other proof-of-concept applications of glycomodification.
Dr. Max Soegaard, Senior Vice President R&D and Technology comments:
“We are now witnessing the outcomes of our continuous efforts to enhance and expand the capabilities of our proprietary platform. Through our R&D, we have succeeded in improving not only the quantity but also the features of proteins expressed for vaccine purposes. This patent is a significant testament to the team's dedication, and I am excited to see it come to fruition”
About glycoengineering in Drosophila S2 cells and the prospects
By modifying specific biochemical pathways in our Drosophila S2 cell lines, we enable them to alter the surface properties of the proteins they produce. These modifications can significantly enhance the immune response to a protein, making the resulting vaccine much more effective while also reducing production costs. We are continually developing these GlycoX-S2 cell lines to further refine the ExpreS2™ system's full potential for creating novel vaccines. In June 2024, we presented the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens - see news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.